PVAC (Corixa/Genesis/Medicis).
Corixa, Genesis and Medicis are developing PVAC, an immunomodulator derived from killed Mycobacterium vaccae and licensed from SR Pharma [309860], [312958], for the potential treatment of psoriasis [365490]. In February 2001, phase II trials were ongoing in the US, the Philippines and Brazil for the treatment of moderate-to-severe psoriasis [399066], [405985]. In January 2001, an NDA filing was expected to take place in 2003 [396733]. In January 2002, Medicis and Corixa planned to initiate another phase IIb trial [436398], and by June 2002, two studies in patients with mild-to-moderate plaque psoriasis had began in the US and New Zealand, with the former designed to investigate the use of PVAC in combination with ultraviolet B (UVB) light [453772], [456657], [456836].
Leopold
Claudia S
CS
Department of Dermatology, School of Medicine, University of Califonia, San Francisco, CA 94143-0989, USA. LeopoldC@compuserve.com
Maibach
Howard I
HI
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001428:Bacterial Vaccines / Q000494:pharmacology / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic / Q000706:statistics & numerical data; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data; D006801:Humans; D009161:Mycobacterium / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; C080550:Mycobacterium w vaccine